Impact of enzalutamide and sequential flutamide and enzalutamide therapy for castration-resistant prostate cancer after bicalutamide-combined androgen blockade therapy onoverall survival: A follow-up study of randomized phase 2 trial (OCCU-CRPC study).

Taro Iguchi,Satoshi Tamada,Minoru Kato,Sayaka Yasuda,Taiyo Otoshi,Y. Machida,Tetsuji Ohmachi,Keiichi Ishii,Hiroyuki Iwata,Shinji Yamamoto,Tomohiro Kanamaru,Kazuya Morimoto,T. Hase,Koichiro Tashiro,Koji Harimoto,Takashi Deguchi,Takahisa Adachi,Katsuki Iwamoto,Yoshinori Takegaki,Tatsuya Nakatani

Impact of enzalutamide and sequential flutamide and enzalutamide therapy for castration-resistant prostate cancer after bicalutamide-combined androgen blockade therapy onoverall survival: A follow-up study of randomized phase 2 trial (OCCU-CRPC study).

2019

5042Background: In Asia, bicalutamide-combined androgen blockade (CAB) is widely used to treat metastatic or locally advanced prostate cancer. Enzalutamide (ENZA) shows benefits in men with metasta...

Keywords:

Flutamide
Blockade
Prostate cancer
Castration
Oncology
Androgen
Pathology
Bicalutamide
Medicine
Enzalutamide
Internal medicine
castration resistant
follow up studies

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations